Literature DB >> 15875150

Hemojuvelin: a supposed role in iron metabolism one year after its discovery.

Peter Celec1.   

Abstract

The discovery of hemojuvelin and its association with juvenile hemochromatosis are important not only for the diagnostics of this rare severe disease but also for the understanding of the complex mechanism of iron metabolism regulation. Currently, the physiological role of hemojuvelin is obscure. Recent experimental and clinical studies indicate that hemojuvelin will probably be a regulator of hepcidin, similar to HFE and transferrin receptor 2. However, in contrast to transferrin receptor 2, which is relevant in the hepcidin response to changes in transferrin saturation, HFE and especially hemojuvelin seem to be involved in the inflammation-induced hepcidin expression. Hepcidin, generally accepted as a hormone targeting enterocytes and macrophages, decreases iron absorption from the intestinal lumen and iron release from phagocytes. This mechanism explains the central role of hepcidin and, indirectly, its regulator, hemojuvelin, in the pathogenesis of hemochromatosis but also in anemia of chronic disease. Further basic and clinical research is needed to uncover the details of hemojuvelin pathophysiology required for potential pharmacological interventions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875150     DOI: 10.1007/s00109-005-0668-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  37 in total

Review 1.  The clinical relevance of new insights in iron transport and metabolism.

Authors:  Pierre Brissot; Marie-Bérengère Troadec; Olivier Loréal
Journal:  Curr Hematol Rep       Date:  2004-03

2.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

3.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

4.  Hepatic and extrahepatic expression of the new iron regulatory protein hemojuvelin.

Authors:  Alejandra Rodriguez Martinez; Onni Niemelä; Seppo Parkkila
Journal:  Haematologica       Date:  2004-12       Impact factor: 9.941

Review 5.  Haemochromatosis: novel gene discovery and the molecular pathophysiology of iron metabolism.

Authors:  W Griffiths; T Cox
Journal:  Hum Mol Genet       Date:  2000-10       Impact factor: 6.150

6.  Regulation of transferrin receptor 2 protein levels by transferrin.

Authors:  Aeisha Robb; Marianne Wessling-Resnick
Journal:  Blood       Date:  2004-08-19       Impact factor: 22.113

7.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Authors:  Antonella Roetto; George Papanikolaou; Marianna Politou; Federica Alberti; Domenico Girelli; John Christakis; Dimitris Loukopoulos; Clara Camaschella
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

8.  Hereditary hemochromatosis: is the gene race over?

Authors:  Paolo Gasparini; Clara Camaschella
Journal:  Eur J Hum Genet       Date:  2004-05       Impact factor: 4.246

9.  Hepcidin is decreased in TFR2 hemochromatosis.

Authors:  Elizabeta Nemeth; Antonella Roetto; Giovanni Garozzo; Tomas Ganz; Clara Camaschella
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

10.  Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis.

Authors:  Carmela Lanzara; Antonella Roetto; Filomena Daraio; Silvain Rivard; Romina Ficarella; Hervey Simard; Timothy M Cox; Mario Cazzola; Alberto Piperno; Anne-Paule Gimenez-Roqueplo; Paola Grammatico; Stefano Volinia; Paolo Gasparini; Clara Camaschella
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  1 in total

Review 1.  Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy.

Authors:  Gavin Y Oudit; Maria G Trivieri; Neelam Khaper; Peter P Liu; Peter H Backx
Journal:  J Mol Med (Berl)       Date:  2006-04-08       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.